AstraZeneca PLC (AZN)

54.58 -1.73 (-3.07%) At close: 04:00PM EDT

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
44 20 3749 5000
https://www.astrazeneca.com

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full-time employees: 83,100

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Pascal Soriot D.V.M., M.B.A.	CEO & Exec. Director	5.15M	N/A	1959
Dr. Aradhana Sarin M.D.	CFO & Exec. Director	3.81M	N/A	1975
Mr. Marc Dunoyer	CEO of Alexion & Chief Strategy Officer	1.8M	N/A	1952
Ms. Pam P. Cheng	EVP of Operations & Information Technology and Member of External Sustainability Advisory Board	N/A	N/A	1971
Mr. Chris Sheldon	Head of Investor Relations	N/A	N/A	N/A
Mr. Jeffrey Pott	Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board	N/A	N/A	N/A
Ms. Katarina Ageborg	EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board	N/A	N/A	N/A
Gonzalo Vina	Head of Global Media Relations	N/A	N/A	N/A
Dr. Menelas Pangalos Ph.D.	EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board	N/A	N/A	1967
Dr. Ruud Dobber Ph.D.	Exec. Vice-Pres of BioPharmaceuticals Bus. Unit	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Corporate governance

AstraZeneca PLC’s ISS governance QualityScore as of 1 September 2022 is 4. The pillar scores are Audit: 3; Board: 7; Shareholder rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.